drugset / Trial / NCT00240318

A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)

NCT00240318 ↗

Phase 3 Completed 450 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries

Timeline

Start
2002-11
Primary completion
2005-11
Completion
2005-11

Outcome

Met primary endpoint

paper significant regression of atherosclerosis for all 3 prespecified IVUS measures of disease burden. PMID 16533939 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 40 mg —